GO
Loading...

Enter multiple symbols separated by commas

Mergers and Acquisitions Acquisitions

More

  • PARIS/ HELSINKI, July 30- Shares in telecom network gear makers Nokia and Alcatel-Lucent jumped on Thursday after both posted strong second-quarter results, giving a positive signal ahead of their pending merger. Nokia's 15.6 billion euro acquisition of Alcatel-Lucent announced in mid-April aims to position the company to better compete with market...

  • LONDON, July 30- AstraZeneca revenue fell by a smaller-than-expected 7 percent in the second quarter, as income from spinning off assets offset generic competition to older medicines and a strong dollar. Chief Executive Pascal Soriot, who fended off a $118 billion takeover attempt by Pfizer last year, is banking on a promising pipeline of new drugs-...

  • July 29- PartnerRe Ltd, the reinsurance company that has a $6.6 billion merger agreement with Axis Capital Holdings, is now willing to negotiate a new deal with rival suitor Exor SpA, according to people familiar with the matter. This would be the first time that Bermuda- based PartnerRe negotiates a potential merger with Exor since the Italian investment...

  • FRANKFURT, July 29- Germany's HeidelbergCement has re-emerged as a global M&A player with the 6.7 billion-euro takeover of Italcementi, after spending the best part of a decade repairing the damage from its last major acquisition. But on Tuesday night, the firm announced an agreement to buy 45 percent of Italcementi for 1.67 billion euros and bid for the rest,...

  • Jarden CEO: Don't need deals to make our numbers Wednesday, 29 Jul 2015 | 10:44 AM ET
    Jarden CEO: Don't need deals to make our numbers

    Jarden Corp. CEO James Lillie, discusses the company's growth strategy after the acquisition of disposable cutlery maker Waddington, and the state of the consumer.

  • LONDON, July 29- British investor Neil Woodford is backing a start-up biopharmaceutical firm whose first venture will be to launch clinical trials of three drugs developed by Novartis. It said has raised $119 million from Woodford Investment and Invesco Perpetual among others, and has acquired drug programmes from Novartis for the treatment of brittle bone...

  • Belgium's Solvay to buy US Cytec for $5.5 billion Wednesday, 29 Jul 2015 | 4:55 AM ET

    BRUSSELS— Belgium's chemical group Solvay has announced it will buy U.S.-based Cytec for $5.5 billion, making it the second biggest company in the aerospace composite materials market. In Wednesday's announcement, CEO Jean-Pierre Clamadieu said that the proposed acquisition "marks a major step change in Solvay's portfolio upgrade" to expand into the...

  • FRANKFURT, July 28- German drugs packaging firm Gerresheimer has agreed to buy U.S. plastic vial maker Centor for $725 million in cash, giving it a leading position in the world's biggest drugs market and lifting its shares to an all-time high. Shares in Gerresheimer jumped more than 15 percent to 65.33 euros, valuing the company at 2.05 billion euros.

  • Reynolds American beats 2Q profit forecasts Tuesday, 28 Jul 2015 | 7:34 AM ET

    WINSTON SALEM, N.C.— Reynolds American reported a surge in second-quarter profit with cigarette prices and volume rising. Earnings, adjusted for non-recurring gains, came to $1.02 per share, which was still 8 cents better than analysts had expected, according to a poll by Zacks Investment Research. It recently closed on a $25 billion takeover of Newport seller...

  • Merck& Co.' s second-quarter profit plunged by two-thirds, hammered by the sale of its consumer business, unfavorable currency exchange rates, lower sales of some key drugs and hefty one-time charges. The world's fifth-biggest drugmaker by revenue beat modest Wall Street expectations and raised its full-year profit forecast by a dime per share, but shares...

  • Gerresheimer buys U.S. plastic vials maker Centor Tuesday, 28 Jul 2015 | 6:44 AM ET

    FRANKFURT, July 28- German drugs packaging firm Gerresheimer has agreed to buy U.S. plastic vial maker Centor for $725 million in cash, giving it a leading position in the world's biggest drugs market and lifting its shares to an all-time high. Shares in Gerresheimer jumped more than 15 percent to 65.33 euros, valuing the company at 2.05 billion euros.

  • July 28- Hikma Pharmaceuticals Plc. *Acquires Roxane Laboratories, transforming its position in us generics market. *Under terms of acquisition, on closing of transaction Hikma will pay gross consideration of $1.18 billion in cash and will issue 40 million new Hikma shares to Boehringer.

  • NEW YORK, July 27- Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger. As head of Actavis, he then sealed a $66 billion purchase of Botox-maker Allergan, beating out rival suitor Valeant...

  • Comcast, Discovery renew distribution agreement Monday, 27 Jul 2015 | 3:17 PM ET

    Under the deal, Comcast's Xfinity TV customers in the United States will get Discovery's 12 U.S. networks, allowing them to access both past and current Discovery content on mobile devices for the first time. Discovery and Comcast had previously clashed over Comcast's scuttled deal to acquire Time Warner Cable Inc earlier this year. Comcast had accused...

  • Allergan to own 10% stake in Teva Monday, 27 Jul 2015 | 3:14 PM ET
    Allergan to own 10% stake in Teva

    CNBC's Meg Tirrell reports Teva is buying Allergan's generic drugs unit, giving Allergan a 10 percent stake in Teva.

  • NEW YORK, July 27- Allergan CEO Brent Saunders said on Monday the company will use the $36 billion it nets from the sale of its generics business to Teva for more deals, including large, "transformational" merger opportunities. Saunders, who led the $66 billion combination of Actavis and Allergan that closed only a few months ago, told investors that it would use the...

  • Teva to acquire Allergan generics unit Monday, 27 Jul 2015 | 10:08 AM ET
    Teva to acquire Allergan generics unit

    Shares of Allergan and Teva are higher after the announcement Teva will acquire Allergan's generics unit for $40.5 billion, with CNBC's Meg Tirrell.

  • TEL AVIV, July 27- Teva Pharmaceutical Industries has agreed to buy Allergan Plc's generic drugs business for $40.5 billion in a cash and stock deal that will turn the Israeli company into one of the world's largest pharmaceutical firms. It also will allow Dublin- based Allergan, the third-largest generic drugmaker in the United States, to focus on branded drugs...

  • The operator from northwest Spain was bought by Zegona, formed by Eamonn O'Hare and Robert Samuelson, who helped build up and then sell Virgin Media in 2013.. The deal is the fourth big telecoms deal in Spain in the last 18 months, after Vodafone bought Ono, Orange snapped up Jazztel and Euskaltel last week agreed an offer for R Cable. It will fund the acquisition with...

  • JERUSALEM— Israel's Teva Pharmaceutical Industries Ltd. said Monday it is purchasing Dublin- based Allergan PLC's generic pharmaceuticals business for $40.5 billion, in what Israeli analysts called the largest-ever acquisition by an Israeli company. Statements from both companies say the deal will see Allergan receive $33.75 billion in cash and shares...